login
Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

US PYTHAGORAS data shows Aorfix is promising for patients with extremely tortuous anatomy


Tuesday, 12 Jun 2012 10:27
AorFix
AorFix


Lombard today announced the high angle clinical data results from the US PYTHAGORAS trial of its endovascular stent graft Aorfix. Data suggest that Aorfix has the potential to provide a less invasive treatment option for abdominal aortic aneurysm patients with highly angulated neck anatomy.


The unique data set, presented at the Society of Vascular Surgery (SVS) Annual Meeting (7–9 June, USA) by Mark Fillinger of Dartmouth Hitchcock Medical Centre, New Hampshire, USA, featured results from the world’s first and largest multicentre EVAR clinical trial studying patients with angles greater than 60 degrees.

Two hundred and five patients were recruited in the trial and the data resulted from 143 patients with highly-angulated aortic necks (angles between 60 and 110 degrees). Treatment of this patient group is not indicated in any stent grafts currently available in the USA.

The data presented showed that Aorfix performed well in extreme aortic neck angulations. Outcomes such as freedom from major adverse events (MAEs, as defined by the SVS) at 30 days and 365 days, were significantly lower than in patients undergoing open surgical repair (81.1% vs. 56.4%, p<0.0001 and 75.5% vs. 54.5%, p<0.0001 respectively). Although not tested in this trial, Fillinger noted that the outcomes were similar to EVAR trials of other stent grafts in much less severe anatomy.

The PYTHAGORAS trial’s results were achieved despite the inclusion of patients with predictors of worse short and long-term outcomes such as:

  • age (75.4+/-8 years vs. 69.2 +/-7 years, p=0.001);

  • proportion of female patients (35% vs. 20%, p=0.015);

  • congestive heart failure (14% vs. 4%, p=0.029); and

  • high neck angles (83+/-15 degrees, compared to SVS control group: 48+/-22 degrees, p<0.05)

“Aorfix has produced promising results in this extremely challenging patient group with high neck angles whose only treatment option currently is open surgical repair. Once available in the US, Aorfix should provide clinicians with a versatile option for treating patients with challenging abdominal aortic aneurysm anatomy, significantly expanding our ability to treat this condition in a minimally invasive fashion,”Fillinger said.

Simon Hubbert, chief executive of Lombard Medical said, “We are very pleased with the US PYTHAGORAS data, further evidence that Aorfix is an excellent treatment option for patients with extremely tortuous anatomy and who previously had no endovascular options. Our work supporting the US approval process for Aorfix is on track and we continue to anticipate US approval by the end of the year.”

Aorfix is currently commercially available in Europe and Lombard expects to launch the stent graft in the USA later this year, subject to FDA approval.




Add New Comment

Most popular


Biolas introduces VariClose in Europe
Thursday, 16 Jul 2015
After the European launch in April 2015, Biolas has introduced the VariClose Vein Sealing Systems in the European market for the treatment of varicose veins. Biolas introduces VariClose in Europe

Lombard Medical acquires EVAR stent graft developer Altura Medical
Friday, 31 Jul 2015
Altura Medical has developed an ultra-low profile endovascular stent graft technology that, according to Lombard, offers a simple and predictable solution for the treatment of standard abdominal ... Lombard Medical acquires EVAR stent graft developer Altura Medical

Sorry, I don’t speak IR
Wednesday, 12 Aug 2015
Two recently published papers in the Journal of Vascular and Interventional Radiology (JVIR) reveal that patient materials in interventional radiology available online are way above the understanding ... Sorry, I don’t speak IR

Features


Patient selection is key for SIRT with first-line chemotherapy
Tuesday, 18 Aug 2015
Ricky Sharma, professor and honorary consultant of Clinical Oncology at the University of Oxford and Oxford University Hospitals Trust tells Interventional News: “We need to know more about patient ... Patient selection is key for SIRT with first-line chemotherapy

Choosing horses for courses: Using liquid agents to embolize endoleaks
Monday, 27 Jul 2015
Robert Morgan, vascular interventional radiologist, St Georges Hospital, London, UK, tells Interventional News why he uses liquid embolic agents, such as ethylene vinyl oxide copolymer (EVOH-based) ... Choosing horses for courses: Using liquid agents to embolize endoleaks

Profiles


Lindsay Machan
Thursday, 28 May 2015
“Focusing on maximising rewards has sidelined more ideas than it has helped individual inventors. S... Lindsay Machan

Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions